Abstract
Purpose of Review
Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed. Transthyretin-derived amyloidosis accounts for 18% of all cases of cardiac amyloidosis. Thus, the study’s purpose is to provide a comprehensive review of transthyretin cardiac amyloidosis.
Recent Findings
Wild-type transthyretin (ATTRwt) protein causes cardiac amyloidosis sporadically, with 25 to 36% of the population older than 80 years of age are at risk to develop a slowly progressive, infiltrative amyloid cardiomyopathy secondary to ATTRwt. In contrast, hereditary amyloidosis (ATTRm) is an autosomal dominant inherited disease associated with more than 100 point mutations in the transthyretin gene and has a tendency to affect the heart and nervous system. Up to 4% of African-Americans carry the Val122Ile mutation in the transthyretin gene, the most prevalent cause of hereditary cardiac amyloidosis in the USA.
Summary
Identifying transthyretin cardiac amyloidosis requires increased awareness of the prevalence, signs and symptoms, and diagnostic tools available for discrimination of this progressive form of cardiomyopathy associated with left ventricular hypertrophy. While there are no FDA-approved medical treatments, investigation is underway on agents to reduce circulating mutated transthyretin.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2014;21(4):221–4. doi:10.3109/13506129.2014.964858.
Cornwell GG, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618–23.
Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002;99(Suppl 4):16427–32. doi:10.1073/pnas.202495199.
Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21–9. doi:10.1056/NEJMoa1404852.
Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159(5):864–70. doi:10.1016/j.ahj.2010.02.006.
•• Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2015;22(3):171–4. doi:10.3109/13506129.2015.1051219. This study revealed the significant prevalence of amyloidogenic transthyretin mutations in the African-American population.
Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV, et al. Transthyretin cardiac amyloidosis in black Americans. Circ Heart Fail. 2016;9(6):e002558. doi:10.1161/CIRCHEARTFAILURE.115.002558.
Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest. 1989;83(3):836–43. doi:10.1172/JCI113966.
Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47(1):127–36.
Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607–14. doi:10.1016/j.ahj.2009.08.006.
Buxbaum J, Jacobson DR, Tagoe C, Alexander A, Kitzman DW, Greenberg B, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47(8):1724–5. doi:10.1016/j.jacc.2006.01.042.
Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–8. doi:10.1093/eurheartj/ehs123.
Benson MD, Cohen AS. Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann Intern Med. 1977;86(4):419–24.
Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2003;10(3):160–84. doi:10.3109/13506120308998998.
• Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50–7. doi:10.1007/s11897-013-0182-4. This report is a valuable resource for developmental therapies for transthyretin amyloidosis.
Damy T, Costes B, Hagège AA, Donal E, Eicher J-C, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2015; doi:10.1093/eurheartj/ehv583.
Arora S, Arora A, Makkar RPS, Monga A. Clinical vistas: stiff heart syndrome. CMAJ Can Med Assoc J. 2003;168(13):1690.
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898–909. doi:10.1056/NEJM199709253371306.
Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6(4):737–43.
Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594–7.
Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–10. doi:10.1161/01.RES.0000126569.75419.74.
Ton V-K, Mukherjee M, Judge DP. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin Med Insights Cardiol. 2015;8(Suppl 1):39–44. doi:10.4137/CMC.S15719.
Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain–associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9. doi:10.1001/archinte.165.12.1425.
Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135(3):172–90. doi:10.1159/000443200.
Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000;109(3):181–8.
Ishikawa Y, Ishii T, Masuda S, Asuwa N, Kiguchi H, Hirai S, et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int. 1996;46(3):189–94.
Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118(11):1287.e1–7. doi:10.1016/j.amjmed.2005.06.017.
Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM Mon J Assoc Physicians. 1998;91(2):141–57.
Bharati S, Lev M, Denes P, Modlinger J, Wyndham C, Bauernfeind R, et al. Infiltrative cardiomyopathy with conduction disease and ventricular arrhythmia: electrophysiologic and pathologic correlations. Am J Cardiol. 1980;45(1):163–73.
James TN. Pathology of the cardiac conduction system in amyloidosis. Ann Intern Med. 1966;65(1):28–36.
Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62(5):677–86.
Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36(18):1098–105. doi:10.1093/eurheartj/ehu506.
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. doi:10.1161/CIRCULATIONAHA.111.078915.
Santarone M, Corrado G, Tagliagambe LM, Manzillo GF, Tadeo G, Spata M, et al. Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 1999;12(6):533–6.
Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74(5):541–4.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), American Association for Thoracic Surgery, Society of Thoracic Surgeons, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1–62. doi:10.1016/j.jacc.2008.02.032.
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10. doi:10.1016/j.jacc.2007.08.028.
Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol. 1983;52(1):137–46.
Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997;80(11):1491–2.
Eriksson P, Karp K, Bjerle P, Olofsson BO. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Br Heart J. 1984;51(6):658–62.
Wright JR, Calkins E. Clinical-pathologic differentiation of common amyloid syndromes. Medicine (Baltimore). 1981;60(6):429–48.
Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11(1):158–62. doi:10.1016/j.hrthm.2013.10.026.
Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013;24(7):793–8. doi:10.1111/jce.12123.
Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222–228.e1. doi:10.1016/j.ahj.2012.04.015.
Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SDJ, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120–7. doi:10.1093/eurheartj/ehr383.
Ranløv I, Alves IL, Ranløv PJ, Husby G, Costa PP, Saraiva MJ. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med. 1992;93(1):3–8.
Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.
Falk RH, Plehn JF, Deering T, Schick EC, Boinay P, Rubinow A, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59(5):418–22. doi:10.1016/0002-9149(87)90948-9.
Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9. doi:10.1161/CIRCULATIONAHA.113.006242.
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12. doi:10.1161/CIRCULATIONAHA.108.843334.
Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol. 2011;108(3):440–4. doi:10.1016/j.amjcard.2011.03.069.
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64. doi:10.1016/j.jcmg.2009.09.023.
Child JS, Levisman JA. Echocardiographic manifestations of infiltrative cardiomyopathy. A report of seven cases due to amyloid. Chest. 1977;70(6):726–31. doi:10.1378/chest.70.6.726.
Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6(4):737–43.
Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446–52. doi:10.1161/01.CIR.0000068313.67758.4F.
Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart Br Card Soc. 2012;98(19):1442–8. doi:10.1136/heartjnl-2012-302353.
Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411–5. doi:10.1016/j.amjcard.2008.09.102.
Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787–9. doi:10.1016/S0140-6736(03)13396-X.
Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–5. doi:10.1161/01.CIR.0000068314.02595.B2.
Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med. 2008;263(3):294–301. doi:10.1111/j.1365-2796.2007.01888.x.
Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098. doi:10.1161/JAHA.113.000098.
Maurer MS, Kristen AV, Rapezzi C, Suhr OB, Kolluri S, Thibaud D. Cardiac biomarkers in patients with transthyretin amyloidosis as documented in THAOS: the transthyretin amyloidosis survey. Presented at ACC13 as a poster abstract,J Am Coll Cardiol. 2013;61(10_S):doi:10.1016/S0735-1097(13)61244-9.
Austin BA, Tang WHW, Rodriguez ER, Tan C, Flamm SD, Taylor DO, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2(12):1369–77. doi:10.1016/j.jcmg.2009.08.008.
Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–42. doi:10.1016/j.jcmg.2013.08.015.
White JA, Kim HW, Shah D, Fine N, Kim K-Y, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143–56. doi:10.1016/j.jcmg.2013.09.019.
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201. doi:10.1161/CIRCIMAGING.112.000132.
Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–70. doi:10.1016/j.jcmg.2011.03.016.
Gertz MA, Grogan M, Kyle RA, Tajik AJ. Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. Am J Cardiol. 1997;80(1):93–5.
Dhingra S, Krishnani N, Kumari N, Pandey R. Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis. Acta Cytol. 2007;51(6):860–4.
van Gameren II, Hazenberg BPC, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015–21. doi:10.1002/art.21902.
Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54(4):271–99.
Ardehali H, Qasim A, Cappola T, Howard D, Hruban R, Hare JM, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147(5):919–23. doi:10.1016/j.ahj.2003.09.020.
Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723–7. doi:10.1016/j.amjcard.2014.02.030.
Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch Int J Pathol. 2000;436(5):439–48.
Picken MM. Amyloidosis—where are we now and where are we heading? Arch Pathol Lab Med. 2010;134(4):545–51. doi:10.1043/1543-2165-134.4.545.
Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2011;18(4):177–82. doi:10.3109/13506129.2011.630762.
Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9. doi:10.1182/blood-2009-07-230722.
Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–23. doi:10.1002/mus.20821.
Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155–62. doi:10.1007/s10741-014-9464-5.
Griffiths BE, Hughes P, Dowdle R, Stephens MR. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax. 1982;37(9):711–2.
Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104(2):618–20.
Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55(13 Pt 1):1645.
Cassidy JT. Cardiac amyloidosis. Two cases with digitalis sensitivity. Ann Intern Med. 1961;55:989–94.
Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63(6):1285–8.
Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124(9):1079–85. doi:10.1161/CIRCULATIONAHA.110.010447.
Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2013;32(5):563–8. doi:10.1016/j.healun.2013.01.987.
Siegenthaler MP, Martin J, van de Loo A, Doenst T, Bothe W, Beyersdorf F. Implantation of the permanent Jarvik-2000 left ventricular assist device: a single-center experience. J Am Coll Cardiol. 2002;39(11):1764–72.
•• Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases Council, International Society for Heart Lung Transplantation (ISHLT) Pediatric Transplantation Council, International Society for Heart Lung Transplantation (ISHLT) Heart Failure and Transplantation Council, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2016;35(1):1–23. doi:10.1016/j.healun.2015.10.023. Updated listing criteria for heart transplantation, pertinent details on cardiac amyloidosis.
Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78(9):637–43. doi:10.1212/WNL.0b013e318248df18.
Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009;88(2):219–25. doi:10.1097/TP.0b013e3181ac60db.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Anit K. Mankad reports grants from Covance.
Keyur B. Shah reports grants from Alnylam.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Myocardial Disease
Rights and permissions
About this article
Cite this article
Mankad, A.K., Shah, K.B. Transthyretin Cardiac Amyloidosis. Curr Cardiol Rep 19, 97 (2017). https://doi.org/10.1007/s11886-017-0911-5
Published:
DOI: https://doi.org/10.1007/s11886-017-0911-5